Search Results - rsv

9 Results

Sort By:

Mononegavirales Vectors Expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...

Published: 7/25/2024 | Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir

Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene

RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with...

Published: 7/25/2024 | Inventor(s): Cyril Le Nouen, Ursula Buchholz, Peter Collins

Keywords(s): ADDITIONAL, BEARING, Codonpair, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deoptimized, DXXXXX, GENES, Improved, Live-Attenuated, M, Mutations, N, NS1, NS2, P, Pgene, POINT, respiratory, RSV, SH, Syncytial, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Therapeutic and Diagnostic Targets for Severe RSV Infection

Respiratory Syncytial Virus (RSV) infects nearly all children by their second birthday. RSV usually causes mild respiratory illness, however, a subset of patients experience severe infection that require hospitalization. Successful host defense against viral pathogens requires rapid recognition of the virus and activation of both innate and adaptive...

Published: 7/25/2024 | Inventor(s): Daniel Menendez Rendon, Steven Kleeberger, Michael Resnick

Keywords(s): DAXXXX, DBXXXX, DCXXXX, Human, Identifies, Infection, p53, PROMOTER, RESPONSIVE, Risk, RSV, Serious, SNP, TLR8

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Mononegavirales Vectors expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...

Published: 7/25/2024 | Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease

Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response

This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated...

Published: 7/25/2024 | Inventor(s): Larry Anderson, Deborah Moore, Ralph Tripp

Keywords(s): bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Geriatrics

CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus

CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are...

Published: 4/8/2024 | Inventor(s): Larry Anderson, Michael Brown, Ralph Tripp

Keywords(s): adjuvant, CD40, CD40L, CDC Docket Import, CDC Docket Import CDC Prosecuting, Costimulation, COSTIMULATORY, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, LIGAND, OID-NCIRD-DVD, respiratory, RSV, RSV virus, Synctial, Vacccination, Vaccine, virus, VLXXXX, WJXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines

Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine

The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization...

Published: 7/25/2024 | Inventor(s): Jason Gorman, Gilad Ofek, Marie Pancera, Mallika Sastry, Sanjay Srivatsan, Yongping Yang, Lei Chen, Cinque Soto, Tongqing Zhou, Barney Graham, Peter Kwong, Masaru Kanekiyo, Michael Joyce, Baoshan Zhang, Guillaume Stewart-Jones, Jeffrey Boyington, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason McLellan

Keywords(s): CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation

Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral...

Published: 7/25/2024 | Inventor(s): Peter Collins, Brian Murphy, Ursula Buchholz, Stephen Whitehead, Christine Krempl

Keywords(s): ATTENUATE, Attenuated, ATTENUATING, ATTENUATION, Chromosome 7, monosomy, DC5BXX, DC5XXX, DCXXXX, Deletion 7, DXXXXX, GENES, Noonan syndrome, NS1, Promoter-proximal, RSV, RSV virus, RSV/PIV, Syncytial, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VACCINE VECTORS, vaccines, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Codon Optimized Genes for Subunit Vaccines

Available for licensing from the NIH are gene constructs that express immunogenic proteins based on viral genes that have been optimized for expression in mammalian cells. Using vaccine vectors expressing respiratory syncytial virus (RSV) proteins from the optimized genes, this technology was shown to result in a potent RSV-specific cellular immune...

Published: 7/25/2024 | Inventor(s): Teresa Johnson, Barney Graham

Keywords(s): Biotechnology, Codon-modified, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, Gene, Patent Category - Biotechnology, respiratory, RSV, Sequences, Syncytial, Vaccine

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease